Skip to main content
Neha Mehta-Shah, MD, Oncology, Saint Louis, MO

NehaMehtaMehta-ShahMD

Oncology Saint Louis, MO

Physician

Dr. Mehta-Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mehta-Shah's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 800-647-2098
    Fax+1 314-362-3192

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2012
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2009

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • MO State Medical License
    MO State Medical License 2016 - 2025
  • NY State Medical License
    NY State Medical License 2011 - 2018
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
    Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
    Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Aggressive Non-Hodgkin Lymphomas: It's Getting Personal 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Black Patients with CLL Face Shorter Overall Survival
    Black Patients with CLL Face Shorter Overall SurvivalJune 5th, 2022
  • What Is the Optimal Frontline Treatment for PTCL?
    What Is the Optimal Frontline Treatment for PTCL?June 23rd, 2021